Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection
Author(s) -
Irini Sereti,
Shelly J. Krebs,
Nittaya Phanuphak,
James L. K. Fletcher,
Bonnie M. Slike,
Suteeraporn Pinyakorn,
Robert J. O’Connell,
Adam Rupert,
Nicolas Chomont,
Victor Valcour,
Jérôme H. Kim,
Merlin L. Robb,
Nelson L. Michael,
Daniel C. Douek,
Jintanat Ananworanich,
Netanya S. Utay
Publication year - 2016
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciw683
Subject(s) - medicine , immunology , inflammation , systemic inflammation , biomarker , tumor necrosis factor alpha , acute phase protein , c reactive protein , biology , biochemistry
Serious non-AIDS events cause substantial disease and death despite human immunodeficiency virus (HIV) suppression with antiretroviral therapy (ART). Biomarkers of inflammation, coagulation cascade activation, and fibrosis predict these end-organ events. We aimed to determine whether ART initiation during acute HIV infection would attenuate changes in these biomarker levels.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom